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As Americans report ever-growing difficulty affording their prescription drugs, President Donald Trump has come under increasing 
pressure to act. To date, the Trump administration 
has attempted to advance a num-
ber of policy initiatives by means 
of executive action, but it has not 
yet adopted a program that would 
meaningfully assist patients. Most 
recently, the administration pro-
posed a rule that, if finalized, 
would allow states to develop 
programs to import lower-priced 
prescription drugs from Canada, 
with the intent of reducing spend-
ing on drugs by U.S. patients and 
states and increasing access for 
patients.1
A careful review of the impor-
tation proposal, however, suggests 
that it is both unlikely to be suc-
cessful in lowering drug prices 
and possibly unlawful. To the ex-
tent that it would achieve any-
thing at all, it would do so not by 
improving the system for pricing 
drugs in the United States, but by 
outsourcing the responsibility for 
addressing high U.S. drug prices 
to Canada. Far from a bold ini-
tiative to help people afford their 
prescription drugs, the proposal 
seems designed to allow the 
Trump administration to claim 
that it is taking action, even as it 
opposes congressional legislation 
that would sharply curb some 
drug prices.
The legal authority for allow-
ing large-scale importation of pre-
scription drugs from Canada is 
not new. In the 2003 law creating 
Medicare Part D, Congress author-
ized such importation — but 
“only if the Secretary [of Health 
and Human Services (HHS)] cer-
tifies to the Congress” that it will 
both “pose no additional risk to 
the public’s health and safety” 
and “result in a significant re-
duction in the cost of covered 
products to the American consum-
er.”2 Until now, HHS officials 
have been unwilling to make the 
required certification, partly be-
cause the U.S. Food and Drug 
Administration (FDA) could not 
ensure the safety of imported 
drugs and partly because total 
savings attributable to importa-
tion would be small.
But policymakers in states as 
politically diverse as Vermont, 
Florida, Colorado, Maine, and 
New Mexico have been pressur-
ing the Trump administration to 
permit importation. Each of these 
states has passed a law seeking 
the flexibility to purchase lower-
priced Canadian medicines for its 
residents (see map). In response, 
HHS has proposed delegating to 
the states the responsibility of 
creating their own plans for drug 
importation. These state-based im-
portation programs would iden-
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tify a Canadian wholesaler that 
buys drugs directly from manu-
facturers and is willing to sell 
those drugs to partners in the 
United States. The program would 
also have to enlist an American 
wholesaler or pharmacy to pur-
chase the drugs from the Cana-
dian wholesaler. With that ar-
rangement in place, a state would 
then need to show to HHS’s sat-
isfaction that its plan is likely to 
save money and protect patient 
safety. If it did so, HHS would 
allow the state to conduct a 
2-year importation program, sub-
ject to future reauthorization.
Having laid out the rules for 
state programs, the Trump ad-
ministration claims that it is now 
in a position to make the certifi-
cation to Congress that the 2003 
law requires. But that claim is a 
strange one to make, given that 
HHS has not concluded either 
that importing drugs would pose 
no public health risks or that it 
would save money. Rather, HHS 
means to issue a kind of condi-
tional certification to Congress: 
if a state demonstrates that it can 
meet the required conditions, 
then the agency will approve the 
state’s importation plan.
This approach to importing 
drugs from Canada raises at least 
three issues regarding legality 
and feasibility. First, HHS may 
not have the legal authority to 
certify to Congress that entirely 
hypothetical state plans will save 
money and not pose health risks 
until the agency has had an op-
portunity to evaluate them. In-
deed, HHS acknowledges in the 
proposed rule that it is “unable 
to estimate the cost savings” at 
this point, since potential savings 
would depend entirely on the de-
tails of states’ importation pro-
posals. Yet certification ought to 
come after evaluation, not before 
it. As one appeals court has held 
in a similar context, “the very 
structure of the statute” may pre-
clude the agency from making a 
congressional certification in ad-
vance of the facts.3
Second, HHS has offered very 
limited guidance to the states on 
how they might show that im-
portation will reduce costs. In a 
terse two paragraphs, the propos-
al envisions that states could com-
pare the “anticipated acquisition 
costs” or the “current retail cash 
State Legislation on Drug Importation, 2018–2020.
Information is as of March 11, 2020, and is from the National Academy for State Health Policy. The map does not show states that have intro-
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price[s]” of drugs in Canada and 
the United States. Because pre-
scription drugs are far more ex-
pensive in the United States than 
they are in Canada — sometimes 
many times more expensive — 
straightforward price comparisons 
would show that importation 
would save money.
Such a blunt approach, how-
ever, appears certain to yield 
wildly inflated savings estimates. 
Canadian regulators and the phar-
maceutical industry, both of which 
oppose the proposal, would not 
stand by and watch as drugs are 
imported into the United States. 
Regulators might change their 
rules to discourage exportation, 
and the industry might adjust 
contractual terms with Canadian 
entities that would prevent or at 
least deter intermediaries from 
partnering with importation pro-
grams. In addition, any savings 
could accrue to the 
wholesalers conduct-
ing the cross-border 
sale or to the pro-
viders prescribing the imported 
drugs, rather than to U.S. pa-
tients. Importation might still 
save money, at least for some 
drugs,4 but a raw comparison of 
prices in the United States and 
Canada provides very thin sup-
port for that conclusion. Pointing 
specifically to these types of con-
cerns, the FDA has questioned 
“whether this proposed rule could 
yield non-zero benefits.”5 The 
courts could well put a stop to 
such an arbitrary approach to es-
timating savings.
Third, the proposal asks states 
to assemble certain types of infor-
mation to show that importation 
would pose no risks to public 
safety, including information on 
supply-chain security guarantees 
and testing requirements. But it is 
perplexing that the federal gov-
ernment would ask states to gath-
er and submit information that 
the FDA has already collected. It 
may not even be possible for 
states to gather the requested in-
formation — indeed, the proposal 
explicitly acknowledges that states 
“may not know whether” a drug 
they propose to import meets the 
FDA’s requirements.
The administration’s proposal 
is thus both puzzling from a pol-
icy standpoint and legally dubi-
ous. At least some of these prob-
lems could have been avoided if 
the Trump administration had 
moved to adopt its own importa-
tion program, as the 2003 law 
seemingly contemplates.
So why punt to the states? As 
with several of the administra-
tion’s other executive actions on 
drug pricing, the proposal ap-
pears to be political theater, de-
signed to mollify the public and 
restive states without overly an-
tagonizing the pharmaceutical in-
dustry. But the Trump adminis-
tration should get no credit for a 
step of questionable legality that 
will not help the vast majority of 
Americans afford their prescrip-
tion drugs — especially because 
it has rejected reform proposals 
from states that drew the concen-
trated ire of drug manufacturers.
If states and the American 
public want lower drug prices, 
this proposal won’t help. They 
will need to push the federal 
government to do more than pay 
lip service to the urgent need to 
constrain spending on prescrip-
tion drugs.
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Implementing the Cures Act — Bringing Consumer Computing 
to Health Care
Donald W. Rucker, M.D. 
Smartphones and electronic transparency have transformed 
our lives and the U.S. economy. 
Yet health care remains a stark 
exception. When health informa-
tion is available, it tends to be 
accessible only in ways that bind 
patients to their current health 
care providers and insurance 
plans. Medical and cost informa-
tion is far more helpful if patients 
can use it on their own terms, 
with tools of their own choosing. 
In the decades since the passage 
of the Stabilization Act of 1942 
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